ALTHE Stock Overview
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system.
Price History & Performance
|Historical stock prices|
|Current Share Price||€1.20|
|52 Week High||€2.28|
|52 Week Low||€0.91|
|1 Month Change||-5.14%|
|3 Month Change||-14.29%|
|1 Year Change||-29.20%|
|3 Year Change||-9.43%|
|5 Year Change||-78.18%|
|Change since IPO||-90.88%|
Recent News & Updates
|ALTHE||FR Medical Equipment||FR Market|
Return vs Industry: ALTHE underperformed the French Medical Equipment industry which returned -5.9% over the past year.
Return vs Market: ALTHE underperformed the French Market which returned -5.4% over the past year.
|ALTHE Average Weekly Movement||7.0%|
|Medical Equipment Industry Average Movement||7.1%|
|Market Average Movement||6.0%|
|10% most volatile stocks in FR Market||10.2%|
|10% least volatile stocks in FR Market||3.5%|
Stable Share Price: ALTHE is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ALTHE's weekly volatility (7%) has been stable over the past year.
About the Company
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient’s skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.
Theraclion Fundamentals Summary
|ALTHE fundamental statistics|
Is ALTHE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALTHE income statement (TTM)|
|Cost of Revenue||€2.88m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.13|
|Net Profit Margin||-223.28%|
How did ALTHE perform over the long term?See historical performance and comparison
Is Theraclion undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
In this section, we usually try to help investors determine whether Theraclion is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Theraclion has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Theraclion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ALTHE's forecast earnings growth is above the savings rate (0.3%).
Earnings vs Market: Insufficient data to determine if ALTHE's earnings are forecast to grow faster than the French market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALTHE's revenue (81.2% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: ALTHE's revenue (81.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALTHE's Return on Equity is forecast to be high in 3 years time
How has Theraclion performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALTHE is currently unprofitable.
Growing Profit Margin: ALTHE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALTHE is unprofitable, but has reduced losses over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare ALTHE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALTHE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).
Return on Equity
High ROE: ALTHE has a negative Return on Equity (0%), as it is currently unprofitable.
How is Theraclion's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: Insufficient data to determine if ALTHE's short term assets cover its short term liabilities.
Long Term Liabilities: Insufficient data to determine if ALTHE's short term assets cover its long term liabilities.
Debt to Equity History and Analysis
Debt Level: Insufficient data to calculate ALTHE's net debt to equity ratio to determine if it is satisfactory.
Reducing Debt: Insufficient data to determine if ALTHE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALTHE has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALTHE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Theraclion current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALTHE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALTHE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALTHE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALTHE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALTHE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. David Caumartin has been the Chief Executive Officer of Theraclion SA since September 30, 2014. Mr. Caumartin is healthcare industry specialist with experience at GE Healthcare, covering Europe, Middle...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
Experienced Management: ALTHE's management team is seasoned and experienced (7.7 years average tenure).
Experienced Board: ALTHE's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 72.7%.
Theraclion SA's employee growth, exchange listings and data sources
- Name: Theraclion SA
- Ticker: ALTHE
- Exchange: ENXTPA
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €34.449m
- Shares outstanding: 28.71m
- Website: https://www.theraclion.com
Number of Employees
- Theraclion SA
- 102 Rue Etienne Dolet
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.